

July 15, 2025

The Honorable Gary Peters
724 Hart Senate Office Building
Washington, DC 20510

The Honorable James Lankford
731 Hart Senate Office Building
Washington, DC 20510

The Honorable Tim Kaine
231 Russell Senate Office Building
Washington, DC 20510

The Honorable Joni Ernst
260 Russell Senate Office Building
Washington, DC 20510

The Honorable Angus King
133 Hart Senate Office Building
Washington, DC 20510

The Honorable Tom Cotton
326 Russell Senate Office Building
Washington, DC 20510

The Honorable Rick Scott
110 Hart Senate Office Building
Washington, DC 20510

Dear Senators Peters, Lankford, Kaine, Ernst, King, Cotton and Scott,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for the *Mapping America's Pharmaceutical Supply (MAPS) Act* ([S.1784](#)). Your important, bipartisan legislation takes a critical step toward identifying and addressing weaknesses in our pharmaceutical supply chain, which will enhance our ability to anticipate disruptions, prevent drug shortages and strengthen overall resilience.

[Vizient, Inc.](#), the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents \$140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

By establishing a nationwide essential medicines database and gathering more information on key steps in the supply chain, including the locations of sites involved in the production of both active pharmaceutical ingredients and finished dosage forms (along with the amount of materials), the *MAPS Act* builds a framework that would allow for proactive intervention in drug shortage situations. Following the mapping process, your legislation would also require the HHS Secretary to conduct a comprehensive risk assessment of these supply chains. This risk assessment will empower hospitals, health systems and federal agencies to reduce vulnerabilities and ensure patients have continued, uninterrupted access to care. Vizient strongly supports this forward-looking effort to enhance the pharmaceutical supply chain and we look forward to working alongside policymakers and stakeholders to advance this bipartisan effort.

Thank you for your leadership in introducing this bill. Please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,

A handwritten signature in black ink, appearing to read "Shoshana Krilow". The signature is fluid and cursive, with the first name "Shoshana" being more prominent and the last name "Krilow" following in a similar style.

Shoshana Krilow

Senior Vice President, Public Policy & Government Relations

July 15, 2025

The Honorable Doris Matsui
2206 Rayburn House Office Building
Washington, DC 20515

The Honorable Dan Crenshaw
248 Cannon House Office Building
Washington, DC 20515

Dear Representatives Matsui and Crenshaw,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for the *Mapping America's Pharmaceutical Supply (MAPS) Act* ([H.R.4191](#)). Your important, bipartisan legislation takes a critical step toward identifying and addressing weaknesses in our pharmaceutical supply chain, which will enhance our ability to anticipate disruptions, prevent drug shortages and strengthen overall resilience.

[Vizient, Inc.](#), the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents \$140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

By establishing a nationwide essential medicines database and gathering more information on key steps in the supply chain, including the locations of sites involved in the production of both active pharmaceutical ingredients and finished dosage forms (along with the amount of materials), the *MAPS Act* builds a framework that would allow for proactive intervention in drug shortage situations. Following the mapping process, your legislation would also require the HHS Secretary to conduct a comprehensive risk assessment of these supply chains. This risk assessment will empower hospitals, health systems and federal agencies to reduce vulnerabilities and ensure patients have continued, uninterrupted access to care. Vizient strongly supports this forward-looking effort to enhance the pharmaceutical supply chain and we look forward to working alongside policymakers and stakeholders to advance this bipartisan effort.

Thank you for your leadership in introducing this bill. Please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow
Senior Vice President, Public Policy & Government Relations